In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including 340B stakeholder reactions to a provider hearing in the U.S. House and ongoing discussion over a 2027 fiscal year (FY) federal spending package that could include language blocking 340B rebates. The team also discusses major updates in the states, including a newly enacted first-of-its-kind 340B law in the Pacific Northwest, a controversial effort to kill a 340B bill in the Midwest and a closer look into state prescription drug affordability boards (PDABs).
Key Topics Covered:
Capitol Hill Update
Shannon and Luke discuss a recent House Energy & Commerce (E&C) Health Subcommittee hearing on providers' role in health care costs, which focused on the 340B program, among other things. Shannon breaks down what two of the witnesses had to say about the drug discount program. Luke highlights the questions key lawmakers asked witnesses, as well as how two senior Republican committee members called for 340B reforms and support for their 340B ACCESS Act, which has drawn major pushback from provider groups. Shannon also offers an update on the FY 2027 federal appropriations process taking shape on Capitol Hill, noting that a group of bipartisan House lawmakers is pushing to add language to the health spending bill that would block a 340B rebate model's implementation.
Key State Developments
Will discusses "the tale of two states," where high-profile 340B bills in Washington and Kansas faced very different outcomes. He also discusses two recent federal district court rulings in favor of state contract pharmacy laws, which continued a string of mostly favorable legal rulings for the states.
Deep Dive into PDABs
Luke discusses PDABs that are popping up across the states and their potential implications on the 340B program. At least 11 states have created a PDAB or a similar board tasked with addressing high drug prices, with some states granting that board to set upper payment limits on drugs. Luke shares why experts say PDABs could lead to lower 340B savings for covered entities, as well as other impacts on the drug supply chain.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
Each episode is brought to you by one of our great Ultra Diamond sponsors. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to [email protected]. We are very grateful to Proximity for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.